101 
Market Cap
Stock Chart
Antisense - 30 Day Poll
Recent BLOGS About Antisense Add New
Latest Company News
|
Biomed Realty Trust Facilitates Isis Pharmaceuticals in Making Cents of Antisense Technology, an Industrial Info News Alert
Marketwire - Jul 22, 2010 SUGAR LAND, TX--(Marketwire - July 22, 2010) - Researched by Industrial Information Resources (Sugar Land, Texas) -- Biomed Realty Trust Incorporated (NYSE:BMR) (San Diego, California) has ...
|
|
New Therapeutic Avenues for Spinal Muscular Atrophy in Development by ISIS Pharmaceuticals, Inc.
StreetInsider.com - Jul 16, 2010 ISIS Antisense Therapy Program for Spinal Muscular Atrophy 2010 Project Update Isis Pharmaceuticals, Inc. (ISIS) is a biotechnology company in San Diego, CA, that focuses on RNA targeting ...
|
|
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
MarketWatch - Jun 29, 2010 ORLANDO, Fla. and CARLSBAD, Calif., June 29, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that data from seven programs in Isis' broad metabolic disease ...
|
|
We are pleased to announce the upcoming FDA and NIH co-sponsored meeting titled Antisense Oligonucleotide (AON) Therapies in Neuromuscular Diseases.
Families of Spinal Muscular Atrophy - Jun 8, 2010 We are pleased to announce the upcoming FDA and NIH co-sponsored meeting titled Antisense Oligonucleotide (AON) Therapies in Neuromuscular Diseases, taking place on the 27th and 28th September ...
|
|
Reportlinker Adds Gene Therapy - Technologies, Markets and Companies
IT News Online - Jun 3, 2010 NEW YORK, June 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Gene Therapy - technologies, markets and companies http://www ...
|
|
Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3
7thSpace Interactive - Jun 3, 2010 Background and Aim:In recent years, Livin, a new member of IAPs family, is found to be a key molecule in cancers. Researchers consider Livin may become a new target for tumor therapy; however, the ...
|
Website
Videos related to Antisense
Company Profile
Antisense Therapeutics utilizes antisense technology to create, develop and commercialize antisense pharmaceuticals. Two forms of protein translation interfence (both involve interfering with gene expression) have emrged in recent years - both have some similarities.
1. Antisense (emerged in the 1990s)
2. Interfering RNA (siRNA, emerged in the early 2000 era)
Approximate cash reserves September 2009: $3.7 million (the loss for the company in 2008 was $2.6M)
Clinical Trials:
Its lead compound (which is for multiple sclerosis), ATL/TV1102, is a second-generation antisense inhibitor of CD49d, a subunit of very late antigen-4 (VLA-4). The compound was licensed from Isis Pharmaceuticals (California, and they remain a partner & shareholder) and in February 2008, the Company entered into an exclusive, worldwide license agreement with Teva Pharmaceuticals Industries (Teva) to develop and commercialize ATL1102. In June 2008 Teva and Antisense Therapeutics announced the results of the ATL/TV1102 Phase IIa multiple sclerosis (MS) trial and reported that ATL/TV1102 significantly reduced disease activity in patients with relapsing remitting multiple sclerosis (RRMS). Teva then elected not continue its relationship with ANP in March 2010 and caused a significant share price drop.
Given teh Teva decision ANP wil now evaluate its options with respect to further development of ATL1102 with key stakeholders including Isis Pharmaceuticals, ANP’s technology collaboration partner and the original developer of ATL1102. Media reports have stated that it is possible that Isis believes that the quality of the Phase 2 trial results warrant consideration of the further development of ATL1102 and discussions are currently underway between the parties on possible paths forward.
Pre-clinical compounds:
The Company is developing ATL1103 as a second-generation antisense drug for growth and sight disorders.
ATL1101 is an antisense inhibitor of insulin like growth factor 1 receptor, and is intended for prostate cancer.
ATL1102 for asthma.
Possible Upcoming Events:
- 2010 begin clinical trials of ATL1103 for growth and sight disorders
- further toxicology studies on ATL1102
Possible competitors:
- Pharmaxis (Asthma related to ATL1102)
- Isis Pharmaceuticals (click here to access on our USA sister site - requires separate log-in) - Antisense
- Gene Signal (Antisense)
- DendriMed (siRNA)
- Benitec (siRNA)